Publicaciones en colaboración con investigadores/as de Queensland University of Technology (42)

2024

  1. Comparison of Patient Health Questionnaire-9, Edinburgh Postnatal Depression Scale and Hospital Anxiety and Depression – Depression subscale scores by administration mode: An individual participant data differential item functioning meta-analysis

    Journal of Affective Disorders, Vol. 361, pp. 674-683

  2. Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study

    Journal of Neurology

  3. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

  4. The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia

    International Journal of Antimicrobial Agents, Vol. 63, Núm. 2

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Correction: Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies (Critical Care, (2023), 27, 1, (3), 10.1186/s13054-022-04294-5)

    Critical Care

  3. Erratum: Hemorrhage, disseminated intravascular coagulopathy, and thrombosis complications among critically ill patients with COVID-19: An International COVID-19 Critical Care Consortium Study (Critical Care Medicine (2023) 51 (619-631) DOI: 10.1097/CCM.0000000000005798)

    Critical Care Medicine

  4. Hemorrhage, Disseminated Intravascular Coagulopathy, and Thrombosis Complications among Critically Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study∗

    Critical Care Medicine, Vol. 51, Núm. 5, pp. 619-631

  5. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

    Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185

  6. Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations

    Nature Medicine, Vol. 29, Núm. 5, pp. 1201-1210

  7. Neurological manifestations of COVID-19 in adults and children

    Brain, Vol. 146, Núm. 4, pp. 1648-1661

  8. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

    ESMO Open, Vol. 8, Núm. 6

  9. Race and ethnicity in the COVID-19 Critical Care Consortium: demographics, treatments, and outcomes, an international observational registry study

    International Journal for Equity in Health, Vol. 22, Núm. 1

  10. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

    Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92

  11. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

    Journal of Thoracic Oncology, Vol. 18, Núm. 8, pp. 1055-1069

  12. TFOS Lifestyle: Impact of nutrition on the ocular surface: TFOS Lifestyle Workshop: Nutrition report

    Ocular Surface, Vol. 29, pp. 226-271

2022

  1. Acute Heart Failure in the 2021 ESC Heart Failure Guidelines: A scientific statement from the Association for Acute CardioVascular Care (ACVC) of the European Society of Cardiology

    European Heart Journal: Acute Cardiovascular Care, Vol. 11, Núm. 2, pp. 173-185

  2. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  3. Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

    Human Brain Mapping, Vol. 43, Núm. 1, pp. 300-328

  4. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308